The board of XVIVO Perfusion AB (publ) (“XVIVO”) has appointed Christoffer Rosenblad as CEO. Christoffer has had the role of acting CEO since September 27, 2022 and will take up his permanent role immediately.
Read moreXVIVO Perfusion AB (publ) (“XVIVO”) has today on November 30, 2022, completed the acquisition of all shares in XVIVO S.rl., acquired from XVIVO S.r.l., whose operations were transferred from Avionord S.r.l. through a so-called carve out.
Read moreXVIVO continues to build and strengthen the company. XVIVO has a firm strategy plan for the coming five years, and as part of securing the company’s global market leading position Lena Hagman has been appointed COO.
Read moreEarlier this month, Professor David Kaye of The Alfred in Melbourne, Australia, presented late breaking science at the American Heart Association (AHA) 2022 meeting in Chicago from an ongoing study of extended transport time of donor hearts. The impressive results showed that in the first 20 study patients transplanted with donor hearts perfused with the XVIVO heart technology there was no mortality despite very extended transport times, up to 8 hours and 47 minutes.
Read moreThird quarter 2022 (July 1 – September 30)• Net sales amounted to SEK 96.8 million (54.9), corresponding to…
Read more
